Renaissance Technologies’s VYNE Therapeutics VYNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$17.4K Sell
10,543
-104,600
-91% -$173K ﹤0.01% 3476
2025
Q1
$182K Buy
115,143
+90,200
+362% +$143K ﹤0.01% 3093
2024
Q4
$83.6K Sell
24,943
-61,700
-71% -$207K ﹤0.01% 3314
2024
Q3
$163K Buy
86,643
+23,532
+37% +$44.2K ﹤0.01% 3166
2024
Q2
$124K Sell
63,111
-17,465
-22% -$34.4K ﹤0.01% 3144
2024
Q1
$247K Buy
80,576
+34,200
+74% +$105K ﹤0.01% 3157
2023
Q4
$108K Buy
46,376
+20,400
+79% +$47.5K ﹤0.01% 3289
2023
Q3
$105K Sell
25,976
-10,100
-28% -$40.8K ﹤0.01% 3231
2023
Q2
$148K Buy
36,076
+10,495
+41% +$43.1K ﹤0.01% 3364
2023
Q1
$79K Sell
25,581
-22,576
-47% -$69.7K ﹤0.01% 3558
2022
Q4
$130K Sell
48,157
-3,454
-7% -$9.32K ﹤0.01% 3552
2022
Q3
$207K Sell
51,611
-585
-1% -$2.35K ﹤0.01% 3370
2022
Q2
$365K Sell
52,196
-1,421
-3% -$9.94K ﹤0.01% 3342
2022
Q1
$627K Buy
53,617
+3,365
+7% +$39.4K ﹤0.01% 3037
2021
Q4
$923K Sell
50,252
-18,916
-27% -$347K ﹤0.01% 2709
2021
Q3
$1.73M Buy
69,168
+51,894
+300% +$1.3M ﹤0.01% 2202
2021
Q2
$1.09M Buy
+17,274
New +$1.09M ﹤0.01% 2630
2021
Q1
Sell
-6,369
Closed -$725K 3753
2020
Q4
$725K Buy
+6,369
New +$725K ﹤0.01% 2659
2020
Q3
Sell
-4,295
Closed -$535K 3727
2020
Q2
$535K Buy
+4,295
New +$535K ﹤0.01% 2852
2020
Q1
Sell
-2,107
Closed -$704K 3845
2019
Q4
$704K Buy
2,107
+374
+22% +$125K ﹤0.01% 2775
2019
Q3
$559K Buy
1,733
+205
+13% +$66.1K ﹤0.01% 2831
2019
Q2
$659K Buy
1,528
+868
+132% +$374K ﹤0.01% 2882
2019
Q1
$373K Buy
660
+386
+141% +$218K ﹤0.01% 3032
2018
Q4
$81K Sell
274
-161
-37% -$47.6K ﹤0.01% 3254
2018
Q3
$308K Buy
+435
New +$308K ﹤0.01% 3011